Key Takeaways
- First Solar posted Q1 CY2026 revenue of $1.04 billion, beating consensus by 1.4% and delivering 23.6% year‑on‑year growth.
- Adjusted EPS of $3.22 surpassed estimates by 13.8%, while adjusted EBITDA reached $499.5 million, an 8.5% beat with a 47.8% margin.
- The company reaffirmed full‑year revenue guidance of $5.05 billion (midpoint) and raised EBITDA guidance to $2.7 billion, above analyst expectations.
- Growth was driven by record sales in India, the launch of CURE technology at the Perrysburg plant, and cost‑reduction initiatives that expanded gross margin by six percentage points.
- Management remains cautious on U.S. bookings pending clarity on Section 232 tariffs, domestic‑content rules, and trade policy, while planning to scale CURE across its fleet by 2028 and launch a perovskite pilot line in 2027.
- The stock traded around $201.88 after the earnings release, up roughly 2% from the prior close, prompting analysts to monitor technology adoption, policy outcomes, and India demand as near‑term catalysts.
Q1 Financial Performance Beat Estimates
First Solar’s first‑quarter results exceeded Wall Street’s expectations on both the top and bottom lines. Revenue came in at $1.04 billion, 1.4% above the consensus estimate of $1.03 billion and representing a robust 23.6% increase compared with the same quarter a year earlier. Adjusted earnings per share were $3.22, beating the analyst forecast of $2.83 by 13.8%. Adjusted EBITDA reached $499.5 million, an 8.5% surplus over the projected $460.4 million, translating to a healthy 47.8% margin. These figures underscore the company’s ability to convert higher sales into profitability while maintaining strong operational leverage.
Management Commentary on Drivers of Q1 Growth
CEO Mark Widmar attributed the quarter’s outperformance to three primary factors: record‑setting sales in India, the successful rollout of CURE technology at the Perrysburg, Ohio facility, and margin expansion stemming from cost‑reduction measures and benefits of domestic U.S. manufacturing. Widmar emphasized that First Solar’s differentiated cadmium‑telluride (CdTe) technology, combined with its U.S. production footprint, allowed the firm to capture demand from both American and Indian markets. He also noted that lower freight and warehousing expenses played a meaningful role in boosting profitability, and that the company is taking a selective approach to new U.S. contract bookings while awaiting clearer policy direction.
Key Insights: India Market Momentum
India emerged as a standout growth driver, with First Solar achieving record sales in the region during Q1. Demand came from both utility‑scale projects and agricultural installations, where CdTe modules are favored for their superior energy yield in hot climates. Management highlighted that domestic‑content requirements and supportive policy frameworks in India are underpinning near‑term demand. The strong performance in India is expected to keep local production facilities operating at high utilization rates, providing a reliable revenue stream even as U.S. bookings remain tentative.
CURE Technology Rollout and Benefits
The launch of CURE technology at the Perrysburg plant marked a pivotal milestone for First Solar. The company completed the rollout on its first Series 6 line and began ramping production. CURE delivers up to 8% more lifetime energy output than comparable crystalline‑silicon modules, a performance advantage that translates into higher value for customers and potential premium pricing. Full fleet adoption of CURE is planned through 2028, with the majority of the technology‑related revenue benefits anticipated to materialize in 2027 and 2028 as the upgraded modules penetrate the market.
U.S. Manufacturing Advantage and Cost Reductions
First Solar’s U.S. facilities operated at high utilization rates during the quarter, benefiting from the company’s domestic manufacturing base. The upcoming South Carolina finishing plant is expected to further optimize logistics, reduce tariff exposure, and improve compliance with domestic‑content rules while capturing Section 45X tax credits for module assembly. Cost‑reduction initiatives contributed six percentage points of gross‑margin expansion year‑over‑year; specifically, warehouse expenses fell by $22 million versus the prior quarter as part of a broader plan to rationalize $100 million in costs by 2027. These efficiencies helped lift operating margin to 33.1%, up from 26.2% in the same period last year.
Policy, Trade, and IP Considerations
Management repeatedly stressed that near‑term U.S. performance hinges on the outcome of trade‑policy deliberations. Decisions on Section 232 tariffs and possible minimum import prices will shape demand and pricing dynamics for solar modules in the United States. Until regulatory clarity emerges, First Solar is maintaining flexibility in its Southeast Asian production capacity to respond to shifting market conditions. On the intellectual‑property front, the company highlighted ongoing enforcement actions, including a Section 337 investigation at the U.S. International Trade Commission targeting imported TOPCon modules, as part of its strategy to protect its CdTe technology advantage.
Outlook and Catalysts for Future Quarters
Looking ahead, First Solar’s full‑year guidance remains anchored by regulatory developments, the rollout of next‑generation products, and the evolving balance between U.S. and international demand. The firm expects CURE technology adoption to drive higher energy yield and technology‑based revenue adjustments over time, while a perovskite pilot line slated for 2027 will be evaluated for field durability before any broader scale‑up. Analysts will monitor three primary catalysts in the coming quarters: the pace of CURE adoption and its influence on customer bookings, the resolution of key U.S. trade‑policy measures such as Section 232 tariffs and minimum import prices, and the continued strength of Indian demand that sustains high utilization at local facilities. Progress on the perovskite line and any shifts in domestic‑content rules will also be watched closely.
Stock Valuation and Investment Consideration
Following the earnings release, First Solar’s shares traded at approximately $201.88, up roughly 2% from the pre‑announcement price of $197.70, giving the company a market capitalization of about $21.69 billion. The blend of better‑than‑expected quarterly results, a reaffirmed revenue outlook, and raised EBITDA guidance suggests underlying operational strength. However, the stock’s near‑term trajectory will likely be sensitive to how quickly policy uncertainties in the U.S. are resolved and how swiftly the CURE technology translates into incremental revenue. Investors weighing a position should weigh the company’s technological differentiation and cost advantages against the lingering regulatory overhang that could affect U.S. bookings and pricing in the medium term. The full research report, available at no cost to active Edge members, offers a deeper dive into these factors and a more detailed valuation framework.